Loading
A phase 3 trial of Padeliporfin in Prostate cancer, run by Steba Biotech S.A., completed.
Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer is a phase 3 interventional study registered as NCT01875393 by Steba Biotech S.A., with 81 participants recorded, started 2013-05 and reaching its primary completion in 2014-12. Interventions recorded: TOOKAD® Soluble. Conditions recorded: Prostate Cancer.
Linked to the drug Padeliporfin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Steba Biotech, Padeliporfin, Prostate cancer and the tag pipeline.
Shares Steba Biotech, Padeliporfin, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/